EMA Authorised: Juluca (dolutegravir sodium;rilpivirine hydrochloride) — ViiV Healthcare B.V.

View source ↗

Summary

EMA authorised Juluca, a fixed-dose combination of dolutegravir and rilpivirine, for HIV infections, with ViiV Healthcare B.V. as the marketing authorization ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Juluca (dolutegravir + rilpivirine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: ViiV Healthcare B.V.. Decision date: 16/10/2025